Three men (3/10) will be found to have significant prostate cancer after the first biopsy; i.e., seven men (7/10) will be found not to have prostate cancer at this time (false positives); Over the next several years, another two of these men will have significant prostate cancer detected during follow-up; Over an extended period of time, five of the ten men will be found not to have prostate cancer despite further investigation (false positives).

Prostate Specific Antigen is a protein made by the prostate gland, which naturally leaks out into the bloodstream. The PSA test measures the level of PSA in the blood. The test is not always reliable as PSA levels also increase as men get older and due to other conditions of the prostate. See similar questions...

Prostate-specific antigen (PSA) is a substance produced by the prostate gland. This is a test that measures the amount of PSA in the bloodstream. See similar questions...

A: The only way to be 100% sure is to connect the manometer in series to an instrument of known accuracy and test during deflation at a variety of pressures (i.e. 300, 260, 180, 120, 60, etc.) When testing your sphygmomanometer, it is important that you check the accuracy in accordance with national or international standards that may be applicable to your device. See similar questions...

If a PSA test is close to the cut-off value, you may decide to repeat it to make sure it is not a laboratory error. You might immediately investigate your patient for prostatic enlargement, infection or cancer if the PSA is above the cut-off value. See similar questions...

The U.S. Food and Drug Administration (FDA) has approved the PSA test for use in conjunction with a digital rectal exam (DRE) to help detect prostate cancer in men age 50 and older. During a DRE, a doctor inserts a gloved finger into the rectum and feels the prostate gland through the rectal wall to check for bumps or abnormal areas. Doctors often use the PSA test and DRE as prostate cancer screening tests in men who have no symptoms of the disease. See similar questions...

The benefits of screening for prostate cancer are still being studied. The National Cancer Institute (NCI) is currently conducting the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, or PLCO trial, to determine if certain screening tests reduce the number of deaths from these cancers. The DRE and PSA are being studied to determine whether yearly screening to detect prostate cancer will decrease one's chance of dying from prostate cancer. See similar questions...

PSA test results report the level of PSA detected in the blood. The PSA level that is considered normal for an average man ranges from 0 to 4 nanograms per milliliter (ng/ml). A PSA level of 4 to 10 ng/ml is considered slightly elevated; levels between 10 and 20 ng/ml are considered moderately elevated; and anything above that is considered highly elevated. various factors can cause PSA levels to fluctuate, one abnormal PSA test does not necessarily indicate a need for other diagnostic tests. See similar questions...

Detection does not always mean saving lives: Even though the PSA test can detect small tumors, finding a small tumor does not necessarily reduce a man's chance of dying from prostate cancer. PSA testing may identify very slow-growing tumors that are unlikely to threaten a man's life. Also, PSA testing may not help a man with a fast-growing or aggressive cancer that has already spread to other parts of his body before being detected. See similar questions...

Using the PSA test to screen men for prostate cancer is controversial because it is not yet known if the process actually saves lives. Moreover, it is not clear if the benefits of PSA screening outweigh the risks of follow up diagnostic tests and cancer treatments. The procedures used to diagnose prostate cancer may cause significant side effects, including bleeding and infection. Prostate cancer treatment often causes incontinence and impotence. See similar questions...

Scientists are researching ways to distinguish between cancerous and benign conditions, and between slow-growing cancers and fast-growing, potentially lethal cancers. Some of the methods being studied are: PSA velocity: PSA velocity is based on changes in PSA levels over time. A sharp rise in the PSA level raises the suspicion of cancer. Age-adjusted PSA: Age is an important factor in increasing PSA levels. See similar questions...

The goal is to develop the next test so that it continues to give the accurate diagnosis of normal, but also gives an accurate diagnosis of carrier and affected status--with no false allele problem. The new test will change the categories we attach to dogs, and they will be categorized as Normal, Carrier, or Affected. - 02/13/2004 See similar questions...

Testing results indicate a sensitivity of 99% compared to 63% for VMA and 83% to 85% for urinary or plasma catecholamines. See similar questions...

PSA stands for prostate specific antigen. When the prostate is irritated, inflamed, or damaged, the PSA level in the bloodstream rises. The normal range is usually 0 to 4. There may be some variations of normal range based on age and race.* See similar questions...

PSA is an excellent marker for use during and after cancer therapy. Ninety-nine percent of the time, PSA lets a patient know how the cancer is responding to the treatment. See similar questions...

The prostate-specific antigen (PSA) test measures the level of PSA in the blood. A blood sample is drawn and the amount of PSA is measured in a laboratory. PSA is a protein produced by the cells of the prostate gland. When the prostate gland enlarges, PSA levels in the blood tend to rise. PSA levels can rise due to cancer or benign (not cancerous) conditions. Because PSA is produced by the body and can be used to detect disease, it is sometimes called a biological marker or tumor marker. See similar questions...